Cartesian Therapeutics Inc. Common Stock (RNAC)
Stock · NASDAQ · Health Care
$6.27as of 10/16/2026
Price chart
Active signals
RNAC Signal Track Record
How signals performed across all stocks →What RNAC's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +2.1% | 57% | September 17, 2026 |
| Bollinger Band Breakdown | 23 | -4.7% | 39% | February 5, 2026 |
| Bollinger Band Breakout | 21 | -11.6% | 33% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -14.7% | 23% | July 28, 2026 |
| Any 20-session window (baseline) | -4.0% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RNAC
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 75
Fundamentals
- 1-day range
- $6.25$6.62
- Market cap
- $257.38M
- P/E (trailing)
- —
- P/E (forward)
- -1.65
- EPS (trailing)
- $-5.87
- Dividend yield
- —
- Beta
- 0.73
- Avg. volume
- 131.5K
How Cartesian Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 9, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Cartesian Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RNACCartesian Therapeutics Inc. Common Stock$6.27▼ 4.71%Market cap $257.38MP/E —$5.6$11
- AKBAAkebia Therapeutics Inc. Common Stock$0.67▼ 3.74%Market cap $256.03MP/E —$0.7$3.2
- MGNXMacroGenics Inc. Common Stock$3.25▼ 3.56%Market cap $254.89MP/E —$1.29$5.08
- WHWKWhitehawk Therapeutics Inc. Common Stock$2.89▼ 4.93%Market cap $252.78MP/E —$1.97$5.5
- VRXAVeraxa Biotech AG Ordinary Shares$1.11▲ 0.91%Market cap $263.02MP/E —$1.04$27.36
- TRDAEntrada Therapeutics Inc. Common Stock$4.37▼ 8.58%Market cap $266.70MP/E —$4.11$16.45
- ELDNEledon Pharmaceuticals Inc. Common Stock$2.13▼ 6.17%Market cap $267.07MP/E —$1.35$4.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics Inc. Common Stock | $257.38M | — | $6.27 | ▼ 4.71% | $5.6$11 |
| AKBA Akebia Therapeutics Inc. Common Stock | $256.03M | — | $0.67 | ▼ 3.74% | $0.7$3.2 |
| MGNX MacroGenics Inc. Common Stock | $254.89M | — | $3.25 | ▼ 3.56% | $1.29$5.08 |
| WHWK Whitehawk Therapeutics Inc. Common Stock | $252.78M | — | $2.89 | ▼ 4.93% | $1.97$5.5 |
| VRXA Veraxa Biotech AG Ordinary Shares | $263.02M | — | $1.11 | ▲ 0.91% | $1.04$27.36 |
| TRDA Entrada Therapeutics Inc. Common Stock | $266.70M | — | $4.37 | ▼ 8.58% | $4.11$16.45 |
| ELDN Eledon Pharmaceuticals Inc. Common Stock | $267.07M | — | $2.13 | ▼ 6.17% | $1.35$4.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 7.01M
- Total value held
- $42.84M
- Institutional holders
- 79
- Unknown2.24M
- Unknown799.7K
- Unknown599.1K
- Unknown407.6K
- Unknown330.0K
- Unknown284.3K
- Unknown263.7K
- Unknown251.1K
- Unknown221.7K
- Unknown200.3K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session
Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.
RNAC Presents New Retreatment Data for Descartes-08 at MGFA Session. Cartesian Therapeutics shared additional retreatment data for its lead candidate Descartes-08 in patients with generalized myasthenia gravis. The results were presented at the MGFA scientific session of the 2026 AANEM annual meeting. This update adds to the company's clinical development information and may influence future regulatory discussions.